QMS Medical Allied Services Ltd has acquired an additional 25 percent stake in Saarathi Healthcare for ₹140 million, increasing its total holding to 75 percent. The move strengthens QMS’s position in chronic disease management and patient support services, aligning with its broader healthcare expansion strategy.
QMS Medical Allied Services Ltd has deepened its investment in Saarathi Healthcare Pvt Ltd by acquiring an additional 25 percent stake for ₹140 million. This strategic acquisition boosts QMS’s total ownership to 75 percent, reinforcing its commitment to integrated healthcare solutions. Saarathi Healthcare is known for its expertise in patient adherence programs, chronic disease management, and pharma-linked support services.
Key highlights
- The ₹140 million acquisition was funded through a ₹12.5 crore rights issue opened on September 12, 2025
- The rights issue offered 14.87 lakh equity shares at ₹81 each, with a 1:12 ratio for existing shareholders
- Saarathi Healthcare’s services complement QMS’s diagnostic and medical device offerings, expanding its total addressable market
- The acquisition is expected to enhance operational synergies and drive revenue growth from FY26 onwards
- QMS aims to integrate Saarathi’s platform into its national network, with a focus on Tier 2 and Tier 3 cities
Notable updates
- QMS CMD Mahesh Makhija stated the deal aligns with the company’s long-term goal of building a comprehensive healthcare ecosystem
- Analysts expect improved client retention and deeper pharma partnerships following the acquisition
- The transaction reflects growing investor confidence in value-added healthcare services and digital patient engagement models
Sources: Express Healthcare, BioSpectrum India, India Press Release